Pro-Inflammatory cytokines & neurobehavioral symptoms in breast cancer patients

描述（由申请人提供）：乳腺癌患者的促炎细胞因子和神经行为症状。乳腺癌幸存者报告虚弱的行为症状，如疲劳和神经认知功能障碍，这在一些个体中甚至在治疗前基线就很明显。来自不同研究领域的充分证据表明，与癌症相关的神经行为症状可能至少在一定程度上是由促炎细胞因子网络的激活所驱动的。乳腺癌患者治疗前血清中特异性促炎细胞因子（IL-6、TNF）和可溶性受体的浓度显著高于健康人，具有预后价值；然而，这些治疗前的升高与急性或慢性行为症状的关系尚未得到评估。在乳腺癌幸存者中，循环sIL-6R和IL-1ra水平升高在化疗后几年的女性横断面研究中已成为持续疲劳的重要生物标志物。在这一患者群体中，没有类似的研究发现神经认知功能障碍的生物标志物，也不清楚细胞因子与疲劳或其他行为症状的联系，是在接近诊断期时存在，还是随着时间的推移而演变为“晚期效应”。在这项研究中，我们将在癌症治疗前评估这种关联，并在治疗完成后再次评估这种关联，从而解决这一知识差距。我们将比较至少137名乳腺癌患者在治疗前与两个对照组的相关性，并仅对治疗后的乳腺癌组进行纵向评估。研究结果有望增加我们对与乳腺癌患者神经行为症状相关的可能生物标志物的认识，以便更好地识别和治疗那些有这种影响风险的人。公共卫生相关性：研究结果有望增加对与乳腺癌患者神经行为症状相关的可能生物标志物的认识，以便更好地识别和治疗那些有此类影响风险的患者。

DESCRIPTION (provided by applicant): Pro-inflammatory cytokines and neurobehavioral symptoms in women with breast cancer. Abstract Survivors of breast cancer report debilitating behavioral symptoms, such as fatigue and neurocognitive dysfunction, which are evident in some individuals even at pre-treatment baseline. There is sufficient evidence from varied lines of research to propose that cancer-related neurobehavioral symptoms may be driven, at least in part, by activation of the pro-inflammatory cytokine network. Concentrations of specific pro-inflammatory cytokines (IL-6, TNF) and soluble receptors in serum obtained prior to treatment in breast cancer patients are significantly higher than levels found in healthy individuals and have prognostic value; however, these pre- treatment elevations have not yet been evaluated with respect to their association with either acute or chronic behavioral symptoms. Among survivors of breast cancer, elevated levels of circulating sIL-6R and IL-1ra have emerged as prominent biomarkers of persistent fatigue in cross-sectional studies of women several years post chemotherapy. No similar work has identified biomarkers of neurocognitive dysfunction in this patient population, and it is not known if the cytokine links with fatigue, or other behavioral symptoms, exist closer to the diagnosis period or evolve over time as "late effects". In this study, we will address this knowledge gap as we will evaluate this association prior to cancer treatment, and again following treatment completion. We will compare these associations in a minimum of 137 breast cancer patients relative to two comparison groups at pre-treatment, and longitudinally evaluate only the breast cancer group after treatment. Findings are expected to increase our knowledge about the possible biomarkers associated with neurobehavioral symptoms in breast cancer patients, for the purpose of better identifying and treating those at risk for such effects. PUBLIC HEALTH RELEVANCE: Findings are expected to increase knowledge about the possible biomarkers associated with neurobehavioral symptoms in breast cancer patients, for the purpose of better identifying and treating those at risk for such effects.